DASCERN研究:伊马替尼3个月应答不佳的CML-CP患者早期换用达沙替尼
DASCERN是一项2b期随机研究,纳入伊马替尼一线治疗3个月未达最佳应答的CML-CP成人患者,按2:1随机接受达沙替尼100mg(n=174)或继续伊马替尼≥400mg(n=86)。12个月主要分子学反应(MMR)率分别为29%和13%(P=0.005),支持早期监测并在应答不佳时换用达沙替尼。
要点
- 伊马替尼3个月未达最佳应答者,换用达沙替尼12个月MMR率29% vs 13%(P=0.005)。
- 继续伊马替尼组52%(45例)随后交叉到达沙替尼,2年累积MMR率64% vs 41%。
- 按意向治疗分析2年MMR率两组分别为66%和67%。
核心结论
- 伊马替尼一线治疗3个月应答不佳的CML-CP患者,早期换用达沙替尼可提高12个月MMR率。
研究设计与样本
- 2b期DASCERN随机研究(NCT01593254),成人CML-CP患者按2:1随机接受达沙替尼100mg(n=174)或继续伊马替尼≥400mg(n=86)。
主要发现
- 12个月MMR率达沙替尼组29%、伊马替尼组13%(P=0.005)。
- 随访≥2年,继续伊马替尼组45例(52%)交叉到达沙替尼。
- 考虑交叉后2年累积MMR率达沙替尼组64%、伊马替尼组41%;按意向治疗分析分别为66%和67%。
- 不良事件与两药已知安全性特征一致。
关键数值与推荐
- 主要终点为12个月MMR率:达沙替尼29% vs 伊马替尼13%(P=0.005)。
- 2年累积MMR率:达沙替尼64% vs 伊马替尼41%;意向治疗分析66% vs 67%。
临床怎么用
- 支持对伊马替尼一线治疗患者进行早期监测。
- 伊马替尼3个月应答不佳时,换用达沙替尼可能带来临床获益。
局限性
- 需进一步随访评估早期换药的长期临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patients with suboptimal response to first-line imatinib. Adult patients with CML-CP were randomized (2:1) to receive 100 mg dasatinib (n = 174) or continue imatinib at ≥400 mg (n = 86). The primary endpoint was the rate of major molecular response (MMR) at 12 months, which was 29% (dasatinib) and 13% (imatinib; P = 0.005). After ≥2 years of follow-up, 45 patients (52%) randomized to continue imatinib had crossed over to dasatinib. Considering treatment crossover, the 2-year cumulative MMR rate was 64% with dasatinib and 41% with imatinib (66% and 67%, respectively by intent-to-treat). Adverse events were consistent with the established safety profiles of both drugs. The results of this first prospective study support early monitoring of patients treated with first-line imatinib, and suggest that switching to dasatinib in cases of suboptimal response may offer clinical benefit. Further follow-up is needed to assess the long-term clinical benefit of early switching.
引用
- Cortes JE, Jiang Q, Wang J, et al. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020. PMID: 32265500. doi:10.1038/s41375-020-0805-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。